FDA grants Mylan tentative approval for generic Lamictal

PITTSBURGH, Pa. Mylan Pharmaceuticals has received tentative approval from the Food and Drug Administration for a generic version of Lamictal.

Lamictal, by GlaxoSmithKline is used to treat epilepsy and bipolar I disorder. The generic version, lamotrigine, will be available in 25 mg, 100 mg, 150 mg and 200 mg tablet strengths.

The drug had sales of about $1.97 billion for the 12 months ended Sept. 30, 2007.

Login or Register to post a comment.